Thorne: company and financial brief
Research date: 8 September 2026. Figures below are historical reported results, announced deal values or attributed forecasts, as labelled. None establish an advertising contribution to company growth.
Business
Founded in 1984, Thorne sells supplements positioned around scientific research, quality and practitioner trust. Its historical business combined direct-to-consumer sales with professional/B2B distribution. Current inspected advertising also spans consumer products, health-concern collections, subscription offers and practitioner acquisition. Those routes should not be grouped as one consumer acquisition objective. Thorne company release
Ownership and public/private history
- September 2021: Thorne HealthTech priced its IPO; Nasdaq trading under THRN was expected to begin September 23. Company IPO announcement
- August 28, 2023: L Catterton take-private announced at $10.20 per share, approximately $680 million transaction value. Company announcement PDF
- October 2023: L Catterton completed the acquisition; Thorne became private and ceased Nasdaq trading. Completion release
- August 4, 2026: P&G agreed to acquire Thorne. P&G’s FY2026 10-K directly discloses $3.8 billion, so this value need not rely solely on press reporting. The filing anticipates closing in Q2 fiscal 2027, subject to regulatory approvals and customary conditions. P&G’s fiscal quarter corresponds to October through December 2026. P&G 10-K, Note 15
- As of this research, the checked sources establish a pending agreement, not a completed P&G acquisition. L Catterton is the seller identified in Thorne’s announcement. Thorne August 4 release, P&G announcement
Financial information, with time periods
| Measure | Period | Reported value | Status |
| Net sales | FY2022 | $228.7m | Reported, +24.1% year over year |
| DTC sales | FY2022 | $100.496m | Reported, 43.9% of sales, +44.3% YoY |
| Professional/B2B sales | FY2022 | $128.236m | Reported, 56.1% of sales, +11.8% YoY |
| Net income attributable to common stockholders | FY2022 | $15.7m | Reported GAAP figure |
| Adjusted EBITDA | FY2022 | $24.5m | Company non-GAAP measure |
| Net sales outlook | FY2023 | $280m–$290m | Guidance issued March 2023, not actual results |
| Sales forecast | FY2026 | $650m | Reuters relayed CNBC’s April forecast; not audited actual revenue |
Historical results and guidance: SEC-filed FY2022 earnings release. Forecast: Reuters, August 4, via Investing.com.
Do not use a transaction-value comparison as an investor return calculation: transaction basis, financing and distributions are not reconciled here. Do not call the 2026 forecast realized revenue, or imply that any inspected ads caused the announced valuation. A full current audited private-company financial series was not established.
Five actual selected ad paths
| Source ad | Observed paid destination | Content classification | Purchase/next action observed |
| 1295052622829527 | Creatine | Direct PDP | Product selection and purchase area |
| 1044790091295061 | Products | Collection | Browse product cards; subscription proposition |
| 1757697288594676 | GLP-1 support | Campaign education plus collection | Shop need-based product groupings |
| 4812196869059332 | Truemed | Eligibility/checkout education | Shop products; eligibility assessment explained, not submitted |
| 1724290905475879 | Women’s health | Campaign page | Formula grid and product links |
The Truemed offer concerns potential HSA/FSA eligibility and tax savings, not an unconditional 30% discount. No standalone editorial/listicle pre-sell was found in these five selected paths. This does not establish that Thorne uses none elsewhere. Full input URLs, redirects, capture times and screenshots are preserved in `captures/journeys.json` and copied into the ARMRA package.